• Explore /
  • Poster
  • / ODENZA: A study of patient preference between ODM-201 (darolutamide) and enzalutamide in men with metastatic castrate-resistant prostate cancer (mCRPC).

ODENZA: A study of patient preference between ODM-201 (darolutamide) and enzalutamide in men with metastatic castrate-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Geraldine Martineau

Clinical Research Department, Institut Gustave Roussy, Villejuif, France

Geraldine Martineau , Stéphanie Foulon , Giulia Baciarello , Florence Joly , Remy Delva , Philippe Barthelemy , Yann Neuzillet , Franck Priou , Anne Sophie Hue , Karim Fizazi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT03314324

Citation

J Clin Oncol 37, 2019 (suppl 7S; abstr TPS334)

DOI

10.1200/JCO.2019.37.7_suppl.TPS334

Abstract #

TPS334

Poster Bd #

N10

Abstract Disclosures

Similar Posters

First Author: Geraldine Martineau

First Author: Siyuan S Guo

First Author: Alyssa Liang

First Author: Alexander Shiang